74%
of retail investor accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
74%
of retail investor accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
English (International)
IQVIA Holdings Inc
Closed
SectorHealthcare
178.51 0.22
Overview
Share price change
24h
Min
175.32
Max
182.62
Income | 182M 514M |
|---|---|
Sales | 264M 4.4B |
P/E Sector Avg | 22.228 66.845 |
Profit margin | 11.778 |
Employees | 93,000 |
EBITDA | 1B |
Recommendations | Strong Buy |
|---|---|
12 Months Forecast | +27.54% upside |
Next Earnings | 5 May 2026 |
|---|
Market Cap | -9.7B 30B |
|---|---|
Previous open | 178.29 |
Previous close | 178.51 |
Technical Score
By Trading Central
Confidence
Bullish Evidence
IQVIA Holdings Inc Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
IQVIA Holdings Inc Forecast
Price Target
By TipRanks
27.54% upside
12 Months Forecast
Average 226.86 USD 27.54%
High 256 USD
Low 174 USD
Based on 17 Wall Street analysts offering 12 month price targets forIQVIA Holdings Inc - Dist in the last 3 months.
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About IQVIA Holdings Inc
IQVIA Holdings Inc. engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; strategic planning and design services; and patient and site centric solutions, as well as central laboratory, genomic, bioanalytical, ADME, discovery, and vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company has a collaboration with argenx SE; and a strategic collaboration with NVIDIA Corporation. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. The company is headquartered in Durham, North Carolina.
Live chat